

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vibegron for treating symptoms of overactive bladder ID6300

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Pierre Fabre (vibegron) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bladder and Bowel UK • Bladder Health UK • Kidney Care UK • Kidney Patient Involvement Network • Kidney Research UK • National Kidney Federation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association for Continence Advice • Association of British Neurologists • Association of Renal Technologists • Physicians • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Society of Urogynaecology • National Neuroscience Advisory Group • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Aristo Pharma (fesoterodine) • Aspire Pharma (darifenacin, fesoterodine, solifenacin, tolterodine) • Astellas Pharma (mirabegron, solifenacin) • Aurobindo Pharma – Milpharm (solifenacin) • Brillpharma (oxybutynin) • Brown & Burk (solifenacin) • Celix Pharma (fesoterodine, solifenacin) • Dr. Reddy's Laboratories (fesoterodine) • Genus Pharmaceuticals (fesoterodine, solifenacin) • Ennogen Healthcare (propiverine) • Glenmark Pharmaceuticals (solifenacin,

Provisional stakeholder list for the evaluation of vibegron for treating symptoms of overactive bladder ID6300

Issue date: September 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Society for Vascular Nurses • The Urology Foundation • UK Clinical Pharmacy Association • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<p>trospium)</p> <ul style="list-style-type: none"> • Krka (solifenacin) • Medical Valley Invest (fesoterodine) • MSN Laboratories (solifenacin) • Neon Healthcare (oxybutynin) • Northumbria Pharma (tolterodine) • Pfizer (fesoterodine) • Ranbaxy, a Sun Pharmaceutical Company (solifenacin) • Roma Pharmaceuticals (oxybutynin) • Sandoz (solifenacin, tolterodine) • Strides Pharma (oxybutynin) • SyriMed (oxybutynin) • Tillomed Laboratories (oxybutynin, solifenacin) • Viartis (tolterodine, trospium) • Zentiva (fesoterodine, oxybutynin, solifenacin, tolterodine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group • Cochrane UK • Cochrane Urology • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.